JP2025509193A5 - - Google Patents
Info
- Publication number
- JP2025509193A5 JP2025509193A5 JP2024552449A JP2024552449A JP2025509193A5 JP 2025509193 A5 JP2025509193 A5 JP 2025509193A5 JP 2024552449 A JP2024552449 A JP 2024552449A JP 2024552449 A JP2024552449 A JP 2024552449A JP 2025509193 A5 JP2025509193 A5 JP 2025509193A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- sequence
- fusion protein
- domain
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263316219P | 2022-03-03 | 2022-03-03 | |
| US63/316,219 | 2022-03-03 | ||
| PCT/US2023/063681 WO2023168405A2 (en) | 2022-03-03 | 2023-03-03 | Viral vectors encoding glp-2 receptor agonist fusions and uses thereof in treating short bowel syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509193A JP2025509193A (ja) | 2025-04-11 |
| JP2025509193A5 true JP2025509193A5 (https=) | 2026-03-11 |
Family
ID=87884276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552449A Pending JP2025509193A (ja) | 2022-03-03 | 2023-03-03 | Ｇｌｐ－２受容体アゴニスト融合物をコードするウイルスベクター及び短腸症候群の治療におけるその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250186613A1 (https=) |
| EP (1) | EP4486765A4 (https=) |
| JP (1) | JP2025509193A (https=) |
| KR (1) | KR20240153588A (https=) |
| CN (1) | CN119522285A (https=) |
| AU (1) | AU2023227587A1 (https=) |
| CA (1) | CA3245162A1 (https=) |
| IL (1) | IL315253A (https=) |
| MX (1) | MX2024010774A (https=) |
| WO (1) | WO2023168405A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025106930A1 (en) * | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200801174A1 (ru) * | 2005-10-24 | 2009-02-27 | Сентокор, Инк. | Антитела-миметики glp-2, полипептиды, композиции, способы и применения |
| US9511103B2 (en) * | 2011-04-20 | 2016-12-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity |
| WO2017024198A1 (en) * | 2015-08-06 | 2017-02-09 | The Trustees Of The University Of Pennsylvania | Glp-1 and use thereof in compositions for treating metabolic diseases |
| CN107987170B (zh) * | 2016-10-27 | 2018-12-18 | 浙江道尔生物科技有限公司 | 一种用于治疗肠道疾病的融合蛋白 |
| BR112020003736A2 (pt) * | 2017-08-22 | 2020-09-08 | Shire-Nps Pharmaceuticals, Inc. | polipeptídeos de fusão de glp-2 e usos para tratar e prevenir condições gastrointestinais |
-
2023
- 2023-03-03 WO PCT/US2023/063681 patent/WO2023168405A2/en not_active Ceased
- 2023-03-03 IL IL315253A patent/IL315253A/en unknown
- 2023-03-03 US US18/843,447 patent/US20250186613A1/en active Pending
- 2023-03-03 AU AU2023227587A patent/AU2023227587A1/en active Pending
- 2023-03-03 JP JP2024552449A patent/JP2025509193A/ja active Pending
- 2023-03-03 EP EP23764174.1A patent/EP4486765A4/en active Pending
- 2023-03-03 CA CA3245162A patent/CA3245162A1/en active Pending
- 2023-03-03 KR KR1020247031780A patent/KR20240153588A/ko active Pending
- 2023-03-03 CN CN202380038015.4A patent/CN119522285A/zh active Pending
-
2024
- 2024-09-02 MX MX2024010774A patent/MX2024010774A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508987A5 (https=) | ||
| JP2018537984A5 (https=) | ||
| JP2022500066A5 (https=) | ||
| JP2024054426A5 (https=) | ||
| JP2021520203A5 (https=) | ||
| JP2021531752A5 (https=) | ||
| JP2021513863A5 (https=) | ||
| JP2022531861A5 (https=) | ||
| JP2023543125A5 (https=) | ||
| WO1999058700A1 (en) | Multiviral compositions and uses thereof | |
| JP2021515572A5 (https=) | ||
| JP2021507687A5 (https=) | ||
| RU2018125468A (ru) | Генная терапия офтальмологических нарушений | |
| JP2019502378A5 (https=) | ||
| JP2023534037A5 (https=) | ||
| JP2025509193A5 (https=) | ||
| TW202246501A (zh) | ＳＭＮ１和ｍｉＲ－２３ａ在治療脊髓性肌萎縮中的協同作用 | |
| JP2022505877A5 (https=) | ||
| Okun et al. | Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease | |
| JP2023535121A5 (https=) | ||
| JP2018526994A5 (https=) | ||
| JP2023539247A5 (https=) | ||
| IL298772A (en) | Coding-optimized nucleic acid encoding the SMN1 protein and its use | |
| CN101213305A (zh) | 转基因在哺乳动物中枢神经系统中的可调控型表达 | |
| JP2020510433A5 (https=) |